In short
A groundbreaking clinical trial is underway to evaluate the potential of CCTx-001, a novel chimeric antigen receptor T-cell (CAR-T) therapy, in treating patients with relapsed or refractory acute myeloid leukemia (AML). This phase 1/2 study aims to determine the optimal dosage, assess safety and tolerability, and explore the clinical effectiveness of CCTx-001 in patients who have not responded to or have relapsed after previous treatments.
At a glance
- Study Type
- Phase 1/2 clinical trial
- Treatment
- CCTx-001 (CAR-T cell therapy targeting IL-1RAP)
- Condition
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Primary Objectives
- Determine safe dose, assess safety and tolerability, evaluate clinical activity
- Key Eligibility Criteria
- Adults with active r/r AML, adequate organ function, no active infections
- Administration
- Intravenous infusion
- Main Outcomes Measured
- Safety profile, response rates, survival outcomes, quality of life
What is CCTX-001?
CCTX-001 is an innovative treatment being developed for patients with relapsed or refractory acute myeloid leukemia (AML). It is a type of advanced therapy known as Chimeric Antigen Receptor T Cells (CAR-T) that targets a specific protein called IL-1RAP. This means that CCTX-001 is made from a patient's own immune cells, which are modified in a laboratory to recognize and attack cancer cells more effectively.
Target Condition: Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a type of blood cancer that affects the bone marrow and blood. "Relapsed" means the cancer has come back after treatment, while "refractory" means the cancer has not responded to standard treatments. CCTX-001 is being developed specifically for patients whose AML has either relapsed or become refractory to other treatments, offering hope for those who have limited options.
Clinical Trial Details
CCTX-001 is currently being studied in a clinical trial called RESOLVE AML 001. This is a Phase 1/2 trial, which means it's an early-stage study designed to: Determine the safe and effective dose of CCTX-001 Assess how well patients tolerate the treatment Evaluate how effective CCTX-001 is in treating relapsed or refractory AML The trial is "adaptive," meaning that it can be adjusted based on early results to optimize patient outcomes.
How CCTX-001 Works
CCTX-001 is a type of cell therapy that uses the patient's own immune cells. Here's a simplified explanation of how it works: T cells (a type of immune cell) are collected from the patient's blood through a process called leukapheresis. These T cells are then genetically modified in a laboratory to produce special receptors on their surface called chimeric antigen receptors (CARs). The CARs are designed to recognize and attach to a specific protein called IL-1RAP, which is found on some leukemia cells. The modified T cells (now called CAR-T cells) are grown in large numbers in the lab. The CAR-T cells are then infused back into the patient, where they can find and destroy cancer cells that have the IL-1RAP protein. This personalized approach allows the patient's own immune system to fight the cancer more effectively.
Eligibility Criteria
To participate in the CCTX-001 clinical trial, patients must meet certain criteria. Some key eligibility factors include: Being 18 years or older Having active relapsed or refractory AML Having tried and not responded to standard treatments Being in overall good health apart from the AML There are also specific medical criteria that patients must meet to ensure their safety during the trial. It's important to discuss eligibility with a healthcare provider who can review all criteria in detail.
Potential Benefits
While it's important to remember that CCTX-001 is still in the experimental stage, the potential benefits being studied include: Improved response rates compared to standard treatments for relapsed/refractory AML Longer-lasting remissions Better quality of life for patients with this difficult-to-treat condition The trial will measure these outcomes using various methods, including assessing the complete response rate and monitoring patients' health-related quality of life.
Safety Considerations
As with any new treatment, safety is a top priority in the CCTX-001 trial. The study will closely monitor patients for side effects and complications. Some potential risks associated with CAR-T cell therapies in general include: Cytokine release syndrome (a condition that can cause fever, low blood pressure, and breathing difficulties) Neurological effects Infections The trial includes specific measures to manage these potential side effects and ensure patient safety. Patients in the trial will be closely monitored and receive comprehensive care throughout their participation.